BLRX Stock Overview
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BioLineRx Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.17 |
| 52 Week High | ₪0.70 |
| 52 Week Low | ₪0.17 |
| Beta | 0.93 |
| 1 Month Change | -43.00% |
| 3 Month Change | -47.81% |
| 1 Year Change | -34.77% |
| 3 Year Change | -74.46% |
| 5 Year Change | -88.89% |
| Change since IPO | -99.74% |
Recent News & Updates
Recent updates
Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?
Apr 02
BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?
Aug 25Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?
Apr 05Is BioLineRx (TLV:BLRX) A Risky Investment?
Jun 17Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?
Feb 26Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?
Oct 17Shareholder Returns
| BLRX | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | 0% | 3.2% | 2.9% |
| 1Y | -34.8% | 4.6% | 10.8% |
Return vs Industry: BLRX underperformed the IL Biotechs industry which returned 4.6% over the past year.
Return vs Market: BLRX underperformed the IL Market which returned 10.8% over the past year.
Price Volatility
| BLRX volatility | |
|---|---|
| BLRX Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 8.3% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: BLRX's share price has been volatile over the past 3 months.
Volatility Over Time: BLRX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 79 | Phil Serlin | www.biolinerx.com |
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.
BioLineRx Ltd. Fundamentals Summary
| BLRX fundamental statistics | |
|---|---|
| Market cap | ₪200.25m |
| Earnings (TTM) | -₪230.10m |
| Revenue (TTM) | ₪18.22m |
11.0x
P/S Ratio-0.9x
P/E RatioIs BLRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLRX income statement (TTM) | |
|---|---|
| Revenue | US$4.80m |
| Cost of Revenue | US$3.69m |
| Gross Profit | US$1.11m |
| Other Expenses | US$61.72m |
| Earnings | -US$60.61m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.051 |
| Gross Margin | 23.08% |
| Net Profit Margin | -1,262.79% |
| Debt/Equity Ratio | 73.9% |
How did BLRX perform over the long term?
See historical performance and comparison